277P - Real-world treatment patterns and outcomes among elderly metastatic triple negative breast cancer patients in the United States

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Breast Cancer, Metastatic
Breast Cancer
Geriatric Oncology
Cancer in Special Situations
Presenter Sacha Satram-Hoang
Citation Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365
Authors S. Satram-Hoang1, P. Bajaj2, A. Stein2, K.Q. Hoang1, F. Momin1, P. Cortazar2, C. Reyes2
  • 1Department Of Epidemiology, Q.D. Research, Inc., 95746 - Granite Bay/US
  • 2Us Medical Affairs, Genentech Inc., 94080 - South San Francisco/US

Abstract

Background

Triple negative breast cancer (TNBC) is more aggressive than other breast cancer (BC) subtypes and accounts for up to 20% of all BC. Despite the poorer prognosis, there are no approved targeted treatments available and chemotherapy (chemo) remains the only choice. We examined treatment patterns and outcomes among elderly metastatic TNBC patients (pts) in routine clinical practice.

Methods

Patients were identified from the linked SEER-Medicare database (1/1/2001-12/31/2013). The analysis included TNBC de novo Stage IV pts (n = 776) and pts with distant recurrences following an initial diagnosis of Stage I-III (n = 1851). Pts were ≥66 years and continuously enrolled in Medicare Parts A/B in the year prior to diagnosis. The analysis was stratified by age

Results

The mean age at metastatic diagnosis was 77.6 years and 1259 (48%) pts received treatment with chemo. Compared to 

Conclusions

In this real-world analysis, 52% of elderly TNBC pts did not receive chemo following their metastatic diagnosis. Although the survival benefits of chemo were stronger in the younger cohort, the benefits of treatment were maintained among ≥70 year olds who were also less likely to receive chemo. These findings suggest opportunities exist to improve the clinical treatment of elderly TNBC pts.

Clinical trial identification

Legal entity responsible for the study

Q.D. Research, Inc

Funding

Genentech, Inc.

Disclosure

S. Satram-Hoang, K.Q. Hoang, F. Momin: Research funding to Institution from Genentech. P. Bajaj, A. Stein, P. Cortazar, C. Reyes: Genenetech employment and Roche stock ownership.